Matricelf Ltd. · TASE:MTLF
Matricelf — Investor Presentation (March 2022)
22 slides from Matricelf's investor presentation, March 2022
Slide 1: Autologous 3D Tissue and Organ Production Platform
Autologous 3D Tissue and Organ Production Platform (TASE:MTLF) Corporate Presentation March 2022
Slide 2: Statement Looking Forward and Disclosure
Statement Looking Forward and Disclosure This presentation was prepared by Matricelf Ltd. (“The Company”), as a general presentation about The Company, as such, the information it includes is only an extract, and does not cover all of the information about The Company and its operations. Therefore,
Slide 3: Company Vision
Company Vision To become a global leader in the area of Regenerative Medicine and Tissue Engineering, offering innovative implants for a variety of medical conditions affecting millions of patients worldwide
Slide 4: Matricelf Introduction
Matricelf Introduction • Biotechnology company in the field of tissue engineering and regenerative medicine • Spin-out company from Tel Aviv University, based on years of academic research at Prof Tal Dvir’s laboratory, Head of the Nanotechnology center • Established April 2019 • Completed IPO at TA
Slide 5: Matricelf: Overview and Highlights
Matricelf: Overview and Highlights Innovative approach • Complete autologous 3D tissue implants for a variety of medical conditions Unique advantages • Autologous treatment • Complete 3D tissue implant (cells and matrix) • Cell differentiation within a 3D structure • Thermo-responsive hydrogel enabl
Slide 6: Proprietary Technologies
Proprietary Technologies Autologous 3D implants: • Integration of autologous matrix and cells • Proprietary decellularization of omentum tissue • Thermo-responsive hydrogel • In-gel differentiation of induced Pluripotent Stem Cells (iPSC) • Engineered tissues for several medical indications 3D biopr
Slide 7: Spinal Cord Injury (SCI)
Spinal Cord Injury (SCI) matrice
Slide 8: SCI Program Highlights
SCI Program Highlights Unmet need • No available treatment for SCI - irreversible loss of motor/sensory/autonomic functions • Most developed therapies are synthetic/allogeneic which may lead to an immune response Our solution • 100% autologous tissue engineered product may serve as an ideal solution
Slide 9: Matricelf Platform Generates Autologous Functioning 3D Neural Implants for SCI
Matricelf Platform Genetares Autologous Functioning 3D Neural Implants for SCI .------ ----- ... ............. ------ ... _ ~- ...... ... ' ,' ; ... ... ; I I ... ... '/\ I ,I ... \ '' '' '' ' \ ' \ \ I \ Cells iPSC >- I I induced Pluripotent I I I Stem Cells I I Differentiation I I I I into differe
Slide 10: Functional Neural Implant
Functional Neural Implant ✓ Incorporation of iPSCs within extracellular matrix followed by controlled differentiation ✓ New synapses and neurons creating a neural network ✓ Matured 3D tissue 2 mm
Slide 11: Cell Function within Neural Implants
Cell Function within Neural Implants 50 μm 500 μm Neurite outgrowth of neural implant Neurite network between neural implants 2 mm Lior Wertheim, Adv. Sci. 2022
Slide 12: Mice Treated with Neural Implants Regained Their Walking Abilities
Mice Treated with Neural Implants Regained Their Walking Abilities Control • Two months follow up post spinal hemi-section in mice • “Cat walk” – four limbs motor function and gait analysis • Control group – hemiparesis (circled in red) • Mice treated with neural implants regained their walking abil
Slide 13: Usability Studies with Neural Implants in Porcine
Usability Studies with Neural Implants in Porcine Neural implants placed in a porcine spinal cord cavity
Slide 14: Competitive landscape
Competitive landscape Analysis of alternative technologies AMEX: LCTX NSDQ:NVIV Autologous cells Pluripotent cells Autologous scaffold 3D structure Matricelf develops a one-of-a-kind technology that produces functioning, completely autologous, 3D neural implants
Slide 15: 2021 Key Achievements
2021 Key Achievements • Completed tech-transfer from Tel Aviv University • FDA Pre-IND meeting • TASE IPO (MTLF) ~ USD 7.5M • New lab opening • National Ethics committee approval (Animal trials) • Completed development of human hydrogel • Successfully completed usability studies • Institutional Revi
Slide 16: Management Team
Management Team TAL DVIR, PhD ASAF TOKER, MD TAMAR HAREL ADAR, PhD Founder, CSO CEO VP R&D ALON SINAI TAL BEN NERIAH, MSc. SIGAL RUSSO, CPA Founder, COO Director of Operations CFO
Slide 17: Board of Directors
Board of Directors TAL DVIR, PhD RUTH ARNON, PhD RIVKA CARMI, MD DORON BIRGER member member member Chairman Neomi Enoch, CPA Ori Hershkovitz ALON SINAI member member member 17
Slide 18: Scientific Advisory Board
Scientific Advisory Board NICHOLAS THEODORE, MD MARK TUSZYNSKI, MD PhD Professor of Neurosurgery and Director of The Center for the director of the Johns Neural Repair, University of Hopkins Neurosurgical Spine California, San Diego Center. ECKHARD VON KEUTZ, PhD Chairman of the Advisory Board of th
Slide 19: Financial Figures
Financial Figures • TASE IPO (MTLF) ~ USD 7.5M - 24 million NIS • 22 million NIS in cash and cash equivalents as of December 31, 2021 • Market cap of 107 million NIS as of March 15, 2022
Slide 20: Investment Summary
Investment Summary Significant market • ~300,000 SCI patients in the US today potential • Approximately 17,000 new SCI cases per year in the US • Huge economic impact on society and healthcare systems • Addresses unmet need in a multibillion-dollar market • Estimated cost for care for first year pos
Slide 21: Watch our corporate video
Watch our corporate video at: https://youtu.be/fEqK2N97VJ0
Slide 22: Thank you
Thank you www.matricelf.com asaf@matricelf.com